NO329257B1 - Kryssbundet stivelse med hoyt amyloseinnhold og med funksjonelle grupper som en matriks for frigivning av farmasoytiske midler. - Google Patents
Kryssbundet stivelse med hoyt amyloseinnhold og med funksjonelle grupper som en matriks for frigivning av farmasoytiske midler. Download PDFInfo
- Publication number
- NO329257B1 NO329257B1 NO20004208A NO20004208A NO329257B1 NO 329257 B1 NO329257 B1 NO 329257B1 NO 20004208 A NO20004208 A NO 20004208A NO 20004208 A NO20004208 A NO 20004208A NO 329257 B1 NO329257 B1 NO 329257B1
- Authority
- NO
- Norway
- Prior art keywords
- cross
- cla
- amylose
- amylose starch
- dosage unit
- Prior art date
Links
- 229920000856 Amylose Polymers 0.000 title claims description 49
- 239000008177 pharmaceutical agent Substances 0.000 title claims description 16
- 125000000524 functional group Chemical group 0.000 title description 16
- 229920002472 Starch Polymers 0.000 title description 13
- 235000019698 starch Nutrition 0.000 title description 13
- 239000008107 starch Substances 0.000 title description 12
- 239000011159 matrix material Substances 0.000 title description 8
- 229920001685 Amylomaize Polymers 0.000 claims description 52
- 239000004971 Cross linker Substances 0.000 claims description 27
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 25
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 23
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 238000004132 cross linking Methods 0.000 claims description 16
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 229960005489 paracetamol Drugs 0.000 claims description 13
- 229920001282 polysaccharide Polymers 0.000 claims description 13
- 239000005017 polysaccharide Substances 0.000 claims description 13
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 claims description 13
- 238000013270 controlled release Methods 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 229940127557 pharmaceutical product Drugs 0.000 claims description 11
- 150000001735 carboxylic acids Chemical class 0.000 claims description 9
- 229920005862 polyol Polymers 0.000 claims description 9
- 150000003077 polyols Chemical class 0.000 claims description 9
- 229920000945 Amylopectin Polymers 0.000 claims description 8
- 230000003111 delayed effect Effects 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 5
- QWVCIORZLNBIIC-UHFFFAOYSA-N 2,3-dibromopropan-1-ol Chemical group OCC(Br)CBr QWVCIORZLNBIIC-UHFFFAOYSA-N 0.000 claims description 4
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- FYBFGAFWCBMEDG-UHFFFAOYSA-N 1-[3,5-di(prop-2-enoyl)-1,3,5-triazinan-1-yl]prop-2-en-1-one Chemical compound C=CC(=O)N1CN(C(=O)C=C)CN(C(=O)C=C)C1 FYBFGAFWCBMEDG-UHFFFAOYSA-N 0.000 claims description 3
- 239000004135 Bone phosphate Substances 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 239000005057 Hexamethylene diisocyanate Substances 0.000 claims description 3
- 229920000161 Locust bean gum Polymers 0.000 claims description 3
- 239000011837 N,N-methylenebisacrylamide Substances 0.000 claims description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 150000008064 anhydrides Chemical class 0.000 claims description 3
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 claims description 3
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 150000002357 guanidines Chemical class 0.000 claims description 3
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims description 3
- 150000007928 imidazolide derivatives Chemical class 0.000 claims description 3
- 150000004693 imidazolium salts Chemical class 0.000 claims description 3
- 239000000711 locust bean gum Substances 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical group [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims description 3
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims description 3
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 68
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 50
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 34
- 238000003756 stirring Methods 0.000 description 29
- 239000000725 suspension Substances 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
- 229920000642 polymer Polymers 0.000 description 22
- 239000012153 distilled water Substances 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 11
- 102000013142 Amylases Human genes 0.000 description 10
- 108010065511 Amylases Proteins 0.000 description 10
- 239000004382 Amylase Substances 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- 108090000637 alpha-Amylases Proteins 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 102000004139 alpha-Amylases Human genes 0.000 description 8
- 229940024171 alpha-amylase Drugs 0.000 description 8
- 235000019418 amylase Nutrition 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 150000004804 polysaccharides Chemical class 0.000 description 8
- 239000012429 reaction media Substances 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229960001193 diclofenac sodium Drugs 0.000 description 6
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical group OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- ONRREFWJTRBDRA-UHFFFAOYSA-N 2-chloroethanamine;hydron;chloride Chemical group [Cl-].[NH3+]CCCl ONRREFWJTRBDRA-UHFFFAOYSA-N 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000030538 Thecla Species 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 229920002689 polyvinyl acetate Polymers 0.000 description 3
- 239000011118 polyvinyl acetate Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- WDMUXYQIMRDWRC-UHFFFAOYSA-N 2-hydroxy-3,4-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1O WDMUXYQIMRDWRC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100026367 Pancreatic alpha-amylase Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- PDEDQSAFHNADLV-UHFFFAOYSA-M potassium;disodium;dinitrate;nitrite Chemical compound [Na+].[Na+].[K+].[O-]N=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O PDEDQSAFHNADLV-UHFFFAOYSA-M 0.000 description 2
- 238000003918 potentiometric titration Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- HLXRWTJXGMHOFN-XJSNKYLASA-N Cornin Natural products O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 108010029785 Pancreatic alpha-Amylases Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003625 amylolytic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/028,385 US6284273B1 (en) | 1998-02-24 | 1998-02-24 | Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds |
| PCT/CA1999/000169 WO1999043305A1 (en) | 1998-02-24 | 1999-02-24 | Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20004208D0 NO20004208D0 (no) | 2000-08-23 |
| NO20004208L NO20004208L (no) | 2000-08-23 |
| NO329257B1 true NO329257B1 (no) | 2010-09-20 |
Family
ID=21843160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20004208A NO329257B1 (no) | 1998-02-24 | 2000-08-23 | Kryssbundet stivelse med hoyt amyloseinnhold og med funksjonelle grupper som en matriks for frigivning av farmasoytiske midler. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6284273B1 (he) |
| EP (1) | EP1059915B1 (he) |
| JP (1) | JP2002504508A (he) |
| KR (1) | KR100713702B1 (he) |
| CN (1) | CN1298297A (he) |
| AT (1) | ATE277604T1 (he) |
| AU (1) | AU755069B2 (he) |
| BR (1) | BR9908187A (he) |
| CA (1) | CA2321461C (he) |
| CZ (1) | CZ301010B6 (he) |
| DE (1) | DE69920669T2 (he) |
| HU (1) | HU225045B1 (he) |
| IL (1) | IL137955A (he) |
| NO (1) | NO329257B1 (he) |
| NZ (1) | NZ506437A (he) |
| PL (1) | PL192468B1 (he) |
| PT (1) | PT1059915E (he) |
| TR (1) | TR200003014T2 (he) |
| WO (1) | WO1999043305A1 (he) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100389752C (zh) * | 1978-04-21 | 2008-05-28 | 莱博法姆公司 | 控释组合物 |
| NZ260408A (en) | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| US7022683B1 (en) | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
| DE19927688A1 (de) * | 1999-06-17 | 2000-12-21 | Gruenenthal Gmbh | Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
| US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
| US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
| CA2445110A1 (en) * | 2001-05-01 | 2002-11-07 | Universite Du Quebec A Montreal | Tridimensional biocompatible support structure for bioartificial organs and uses thereof |
| TWI319713B (en) * | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
| DE60322091D1 (de) * | 2002-10-25 | 2008-08-21 | Labopharm Inc | Zubereitungen mit kontrollierter freisetzung |
| US8487002B2 (en) * | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| EP1713498A4 (en) * | 2004-02-09 | 2009-07-15 | Transfert Plus Sec | POLYMERIC MATERIAL CONTAINING COMPOSITION AND ITS USES |
| CA2491665A1 (fr) * | 2004-12-24 | 2006-06-24 | Louis Cartilier | Formulation de comprime pour liberation soutenue de principe actif |
| PL1931346T3 (pl) | 2005-09-09 | 2013-01-31 | Angelini Labopharm Llc | Kompozycja trazodonu do podawania raz na dobę |
| US8241656B2 (en) * | 2005-09-21 | 2012-08-14 | Surmodics, Inc | Articles including natural biodegradable polysaccharides and uses thereof |
| DE602006011764D1 (de) * | 2005-09-21 | 2010-03-04 | Surmodics Inc | In situ okklusionszusammensetzungen mit natürlichen biologisch abbaubaren polysacchariden |
| WO2007105719A1 (ja) * | 2006-03-14 | 2007-09-20 | National University Corporation NARA Institute of Science and Technology | 新規なヘパリン代替材料およびその製造方法 |
| CA2590821A1 (en) * | 2007-06-07 | 2008-12-07 | Universite De Montreal | High-amylose sodium carboxymethyl starch sustained release excipient and process for preparing the same |
| EP2203166B1 (en) * | 2007-10-16 | 2015-05-06 | Paladin Labs Inc. | Bilayer composition for the sustained release of acetaminophen and tramadol |
| CN101161684B (zh) * | 2007-11-23 | 2010-05-19 | 华南理工大学 | 交联羧甲基淀粉的红外线合成方法 |
| AU2008338207A1 (en) | 2007-12-17 | 2009-06-25 | Labopharm (Barbados) Limited | Misuse preventative, controlled release formulation |
| US20100273006A1 (en) * | 2007-12-21 | 2010-10-28 | Akzo Nobel N.V. | Thermosetting polymers |
| WO2009137689A2 (en) | 2008-05-07 | 2009-11-12 | Surmodics, Inc. | Delivery of nucleic acid complexes from particles |
| CA2737247C (en) * | 2008-09-15 | 2016-10-11 | Labopharm Inc. | Starch-based microparticles for the release of agents disposed therein |
| CA2746888C (en) | 2008-12-16 | 2015-05-12 | Labopharm (Barbados) Limited | Misuse preventative, controlled release formulation |
| MX2013000024A (es) | 2010-07-06 | 2013-02-01 | Gruenenthal Gmbh | Nuevas formas de dosificacion gastrorretentivas. |
| US8901092B2 (en) | 2010-12-29 | 2014-12-02 | Surmodics, Inc. | Functionalized polysaccharides for active agent delivery |
| WO2012116434A1 (en) * | 2011-03-01 | 2012-09-07 | 4413261 Canada Inc. (Spencer Canada) | Two speed monolithic system for controlled release of drugs |
| WO2015127537A1 (en) * | 2014-02-27 | 2015-09-03 | B-Organic Films Corp. | Bioactive agents included in functionalized starch having a single helix v-structure |
| SG11201704537QA (en) | 2014-12-19 | 2017-07-28 | Baxter Int | Flowable hemostatic composition |
| CN104784738B (zh) * | 2015-04-03 | 2016-12-07 | 四川大学 | 一种天然缓释多效医用海绵 |
| CN106279453B (zh) * | 2015-05-28 | 2019-12-10 | 易媛 | 交联的高分子化合物及其制备方法、水凝胶、水基压裂液和用途 |
| CN105536058A (zh) * | 2016-01-22 | 2016-05-04 | 青岛中腾生物技术有限公司 | 一种医用淀粉海绵及其制备方法和用途 |
| GB2567493B (en) | 2017-10-13 | 2019-12-18 | Altus Formulation Inc | Starch-based release modifying excipients and pharmaceutical compositions derived therefrom |
| CN111072791A (zh) * | 2019-12-27 | 2020-04-28 | 河南新孚望新材料科技有限公司 | 一种包膜剂用高直链淀粉的制备方法 |
| BR112023019989A2 (pt) * | 2021-03-31 | 2023-11-14 | Hayashibara Co | Método para produção de polímero solúvel em água e método para produção de resina absorvente de água |
| JP7125216B1 (ja) | 2021-03-31 | 2022-08-24 | 長瀬産業株式会社 | 水溶性ポリマーの製造方法、および吸水性樹脂の製造方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4072535A (en) * | 1970-12-28 | 1978-02-07 | A. E. Staley Manufacturing Company | Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules |
| US4369308A (en) * | 1981-07-24 | 1983-01-18 | National Starch And Chemical Corporation | Low swelling starches as tablet disintegrants |
| JPH0791240B2 (ja) * | 1987-04-01 | 1995-10-04 | 株式会社日本触媒 | ２−ハロエチルアミンハロゲン化水素酸塩の製造方法 |
| CA2041774C (en) * | 1990-11-27 | 1994-04-19 | Mircea A. Mateescu | Use of cross-linked amylose as a matrix for the slow release of biologically active compounds |
| JPH06271704A (ja) * | 1993-03-22 | 1994-09-27 | Asahi Chem Ind Co Ltd | 水性易燃性組成物 |
| US5616343A (en) * | 1993-03-25 | 1997-04-01 | Labopharm, Inc. | Cross-linked amylose as a binder/disintegrant in tablets |
| CN1150218C (zh) * | 1994-04-11 | 2004-05-19 | 赫希斯特人造丝公司 | 超吸收性聚合物及其制品 |
| US5830884A (en) * | 1995-01-18 | 1998-11-03 | National Starch And Chemical Investment Holding Corporation | Pharmaceutical products containing thermally-inhibited starches |
| US5593503A (en) * | 1995-06-07 | 1997-01-14 | National Starch And Chemical Investment Holding Corporation | Process for producing amylase resistant granular starch |
| US5667637A (en) * | 1995-11-03 | 1997-09-16 | Weyerhaeuser Company | Paper and paper-like products including water insoluble fibrous carboxyalkyl cellulose |
| CA2173818A1 (fr) * | 1996-04-10 | 1997-10-11 | Francois Chouinard | Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose |
| US5879707A (en) * | 1996-10-30 | 1999-03-09 | Universite De Montreal | Substituted amylose as a matrix for sustained drug release |
| US5807575A (en) * | 1997-02-14 | 1998-09-15 | Rougier Inc. | Manufacture of cross-linked amylose useful as a excipient for control release of active compounds |
-
1998
- 1998-02-24 US US09/028,385 patent/US6284273B1/en not_active Expired - Lifetime
-
1999
- 1999-02-24 AT AT99936029T patent/ATE277604T1/de not_active IP Right Cessation
- 1999-02-24 JP JP2000533104A patent/JP2002504508A/ja active Pending
- 1999-02-24 PL PL342596A patent/PL192468B1/pl not_active IP Right Cessation
- 1999-02-24 PT PT99936029T patent/PT1059915E/pt unknown
- 1999-02-24 BR BR9908187-3A patent/BR9908187A/pt not_active Application Discontinuation
- 1999-02-24 AU AU32420/99A patent/AU755069B2/en not_active Ceased
- 1999-02-24 CA CA002321461A patent/CA2321461C/en not_active Expired - Fee Related
- 1999-02-24 DE DE69920669T patent/DE69920669T2/de not_active Expired - Lifetime
- 1999-02-24 HU HU0100818A patent/HU225045B1/hu not_active IP Right Cessation
- 1999-02-24 WO PCT/CA1999/000169 patent/WO1999043305A1/en active IP Right Grant
- 1999-02-24 IL IL13795599A patent/IL137955A/he not_active IP Right Cessation
- 1999-02-24 EP EP99936029A patent/EP1059915B1/en not_active Expired - Lifetime
- 1999-02-24 NZ NZ506437A patent/NZ506437A/xx unknown
- 1999-02-24 TR TR2000/03014T patent/TR200003014T2/xx unknown
- 1999-02-24 US US09/257,090 patent/US6419957B1/en not_active Expired - Fee Related
- 1999-02-24 KR KR1020007009278A patent/KR100713702B1/ko not_active IP Right Cessation
- 1999-02-24 CN CN99805447A patent/CN1298297A/zh active Pending
- 1999-02-24 CZ CZ20003097A patent/CZ301010B6/cs not_active IP Right Cessation
-
2000
- 2000-08-23 NO NO20004208A patent/NO329257B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE277604T1 (de) | 2004-10-15 |
| PL342596A1 (en) | 2001-06-18 |
| EP1059915B1 (en) | 2004-09-29 |
| BR9908187A (pt) | 2000-10-31 |
| TR200003014T2 (tr) | 2001-02-21 |
| AU755069B2 (en) | 2002-12-05 |
| CN1298297A (zh) | 2001-06-06 |
| US6419957B1 (en) | 2002-07-16 |
| US6284273B1 (en) | 2001-09-04 |
| IL137955A0 (en) | 2001-10-31 |
| JP2002504508A (ja) | 2002-02-12 |
| KR20010034531A (ko) | 2001-04-25 |
| CA2321461C (en) | 2008-04-29 |
| PL192468B1 (pl) | 2006-10-31 |
| NZ506437A (en) | 2003-03-28 |
| DE69920669D1 (de) | 2004-11-04 |
| IL137955A (he) | 2005-12-18 |
| PT1059915E (pt) | 2005-02-28 |
| DE69920669T2 (de) | 2005-11-03 |
| CA2321461A1 (en) | 1999-09-02 |
| KR100713702B1 (ko) | 2007-05-02 |
| HUP0100818A3 (en) | 2001-12-28 |
| NO20004208D0 (no) | 2000-08-23 |
| NO20004208L (no) | 2000-08-23 |
| CZ20003097A3 (en) | 2001-06-13 |
| CZ301010B6 (cs) | 2009-10-14 |
| WO1999043305A1 (en) | 1999-09-02 |
| HU225045B1 (en) | 2006-05-29 |
| AU3242099A (en) | 1999-09-15 |
| EP1059915A1 (en) | 2000-12-20 |
| HUP0100818A2 (hu) | 2001-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329257B1 (no) | Kryssbundet stivelse med hoyt amyloseinnhold og med funksjonelle grupper som en matriks for frigivning av farmasoytiske midler. | |
| Meneguin et al. | Films from resistant starch-pectin dispersions intended for colonic drug delivery | |
| KR100840393B1 (ko) | 조절된 방출용 약학 제형에 사용하기 위한 가교결합된 고아밀로오스 전분 및 이의 제조 방법 | |
| Kamel et al. | Pharmaceutical significance of cellulose: A review | |
| ES2207720T3 (es) | Amilosa sustituida que sirve de matriz para la liberacion continua de medicamentos. | |
| Rubinstein | Natural polysaccharides as targeting tools of drugs to the human colon | |
| AU2001271481A1 (en) | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture | |
| TW574253B (en) | Polymer blends that swell in an acidic environment and deswell in a basic environment | |
| Onofre et al. | Effects of structure and modification on sustained release properties of starches | |
| Li et al. | Structure and colon-targeted releasing property of resistant octenyl succinate starch | |
| Verestiuc et al. | Functionalized chitosan/NIPAM (HEMA) hybrid polymer networks as inserts for ocular drug delivery: Synthesis, in vitro assessment, and in vivo evaluation | |
| George et al. | Preparation and evaluation of chitosan-alginate/carrageenan hydrogel for oral drug delivery in the treatment of diabetes | |
| WO1999009066A1 (en) | Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents | |
| Ambrosio et al. | Superabsorbent cellulose-based hydrogels for biomedical applications | |
| Xiao et al. | Preparation and characterization of a novel pachyman-based pharmaceutical aid. II: A pH-sensitive, biodegradable and biocompatible hydrogel for controlled release of protein drugs | |
| US20100331232A1 (en) | Starch-based hydrogel for biomedical applications | |
| Chebli et al. | Effect of some physical parameters on the sustained drug-release properties of substituted amylose matrices | |
| Melia et al. | Natural polysaccharides in hydrophilic matrices | |
| Khandelwal et al. | Polysaccharides and Natural Gums for Colon Drug Delivery. | |
| MXPA00008227A (en) | Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents | |
| HUT75665A (en) | A drug delivery device and a method of making such device | |
| Steendam | Amylodextrin and poly (DL-lactide) oral controlled release matrix tablets. Concepts for understanding their release mechanisms | |
| Chaurasia et al. | Synthetic polymers as biomaterials for the treatment of colon diseases | |
| Embi et al. | First Order Kinetics of Salicylamide Release from κ-Carrageenan Hard Shell Capsules in Comparison with Gelatin | |
| Keraliya et al. | BIODEGRADABLE NATURAL POLYMERS: CARRIERS FOR COLON TARGETTING DRUG DELIVERY SYSTEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |